share_log

Goldman Sachs Maintains Neutral on Centessa Pharmaceuticals, Raises Price Target to $5

Benzinga ·  Aug 15, 2023 08:44

Goldman Sachs analyst Salveen Richter maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Neutral and raises the price target from $4.5 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment